Table 2 Putative neoepitopes encoding mutations found recurrently in hematological cancers
From: Isolation of T cell receptors targeting recurrent neoantigens in hematological malignancies
Protein | Mutation | Putative epitope | Peptide | HLA-Restriction | Predicted HLA binding affinity (nM) | Hematopoietic and Lymphoid Cancer Frequencies |
|---|---|---|---|---|---|---|
CALR | K385Nfs*47 | RPRTSCREA | CALR-REA | HLA-B*07:02 | 12 | Essential thrombocythemia (31.1%), Myelofibrosis (27.3%) |
SPARPRTSC | CALR-SPA | HLA-B*07:02 | 22 | |||
RMRRTRRKM | CALR-RMR | HLA-B*07:02 | 56 | |||
RPRTSCREAC | CALR-REAC | HLA-B*07:02 | 23 | |||
RMMRTKMRMR | CALRp2 | HLA-A*03:01 | 41 | |||
KMRMRRMRR | CALRp7 | HLA-A*03:01 | 35 | |||
RTRRKMRRK | CALRp15 | HLA-A*03:01 | 54 | |||
FBXW7 | R465C | TVCCMHLHEK | TVC | HLA-A*11:01 | 29 | T-ALL (15.4%), Precursor T cell lymphoblastic lymphoma (15.6%) |
STVCCMHLHEK | STV | HLA-A*11:01 | 65 | |||
HTSTVCCMHLH | HTS | HLA-A*11:01 | 495 | |||
R465H | STVHCMHLH | STVH | HLA-A*11:01 | 78 | ||
TVHCMHLHEK | TVH | HLA-A*11:01 | 43 | |||
P53 | R248Q | SSCMGGMNQR | NQR | HLA-A*11:01 | 177 | Mantle cell lymphoma (9.1%), B-ALL (6.9%), T-ALL (8.6%), Follicular lymphoma (18.5%), AML (7%), MDS (7.3%), CLL (10.9%), T cell lymphoma (18.6%), Burkitt’s lymphoma (18%), Diffuse large B cell lymphoma (12.6%) |
R248W | SSCMGGMNWR | NWR | HLA-A*11:01 | 320 | ||
MyD88 | L265P | RPIPIKYKAM | RPI | HLA-B*07:02 | 20 | MGUS (46.8%), Waldenström’s macroglobulinaemia (86.3%), Diffuse large B cell lymphoma (14.4%) |
SPGAHQKRPI | SPG | HLA-B*07:02 | 40 | |||
IDH2 | R140Q | SPNGTIQNIL | SPN | HLA-B*07:02 | 72 | AML (9.7%), Angioimmunoblastic T cell lymphoma (24.1%) |
DNMT3A | R882H | VSNMSHLAR | VSN | HLA-A*11:01 | 61 | AML (20.4%), MDS (9.1%), T cell lymphoma (25.7%), |
STAT3 | Y640F | QIQSVEPFTK | QIQ | HLA-A*11:01 | 60 | T cell large granular lymphocytic leukaemia (34.3%), Adult T-cell leukemia/lymphoma (21.1%) |